Litigation Details for Pfizer Inc. v. Aurobindo Pharma, Ltd. (D. Del. 2020)

« Back to Dashboard

Pfizer Inc. v. Aurobindo Pharma, Ltd. (D. Del. 2020)

Docket		Date Filed	2020-11-13
Court	District Court, D. Delaware	Date Terminated	2021-10-06
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,723,730
Link to Docket	External link to docket

Details for Pfizer Inc. v. Aurobindo Pharma, Ltd. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-11-13				External link to document

Pfizer v. Aurobindo Pharma, 1:20-cv-01528: Vyndaqel Patent Litigation Summary

Last updated: August 31, 2026

Pfizer Inc. v. Aurobindo Pharma Limited, No. 1:20-cv-01528, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware concerning Aurobindo's abbreviated new drug application for a generic version of Vyndaqel, Pfizer's tafamidis meglumine product. Pfizer asserted U.S. Patent No. 8,309,605, the principal Orange Book patent covering tafamidis meglumine and related pharmaceutical compositions. The case presented a conventional Paragraph IV challenge to Pfizer's branded tafamidis franchise, with generic entry dependent on the patent's validity, enforceability and expiration.

What drug and patents were involved in Pfizer v. Aurobindo?

The litigation involved Vyndaqel, whose active ingredient is tafamidis meglumine. Vyndaqel is approved for the treatment of transthyretin amyloid polyneuropathy in adults with the inherited form of the disease. Pfizer later commercialized Vyndamax, a tafamidis free-acid product, for cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis.[1]

Item	Case detail
Court	U.S. District Court for the District of Delaware
Civil action	1:20-cv-01528
Plaintiff	Pfizer Inc.
Defendant	Aurobindo Pharma Limited and related Aurobindo entities
Litigation type	Hatch-Waxman ANDA litigation
Branded product	Vyndaqel
Active ingredient	Tafamidis meglumine
Patent asserted	U.S. Patent No. 8,309,605
Patent title	Tafamidis meglumine and related pharmaceutical compositions
Judge	Richard G. Andrews
Legal pathway	Paragraph IV patent challenge

Aurobindo's ANDA filing created the statutory basis for Pfizer's lawsuit. An ANDA applicant may certify that an Orange Book patent is invalid, unenforceable or will not be infringed. That certification is commonly called a Paragraph IV certification. Pfizer's filing of an infringement action triggered the statutory 30-month stay of FDA approval, subject to statutory exceptions.[2]

What patent protected Vyndaqel in the Aurobindo litigation?

U.S. Patent No. 8,309,605 was the central patent at issue. The patent claims tafamidis meglumine and pharmaceutical compositions containing the compound. Its commercial importance was substantial because tafamidis is the active pharmaceutical ingredient responsible for the Vyndaqel product's therapeutic effect.

The patent was issued on Nov. 13, 2012, from an application claiming priority to a July 11, 2007 filing. Public patent records identify a July 11, 2028 expiration date for the patent, subject to any applicable patent-term adjustment or other statutory modification.[3]

What did U.S. Patent No. 8,309,605 cover?

The patent estate was narrower than a broad platform patent covering every tafamidis use. Its core relevance was the claimed tafamidis meglumine drug substance and pharmaceutical composition. The scope created several potential litigation issues:

1. Whether the ANDA product contained the claimed tafamidis meglumine form.
2. Whether the proposed formulation met the patent's composition limitations.
3. Whether the patent claims were anticipated or obvious in view of earlier tafamidis disclosures.
4. Whether the asserted claims were adequately supported and enabled.
5. Whether Aurobindo's Paragraph IV notice established a justiciable infringement dispute.

Because ANDA cases evaluate the product described in the proposed regulatory filing, the analysis focuses on the ANDA's formulation, manufacturing process and proposed labeling rather than on commercial conduct after launch.

When does Vyndaqel lose patent exclusivity?

The principal Orange Book patent identified with the Vyndaqel tafamidis franchise expires in 2028. The relevant date for generic launch is not necessarily the expiration date alone. FDA approval timing, pediatric exclusivity, litigation settlement terms, court orders and any applicable regulatory exclusivity can affect the first lawful commercial launch.

Exclusivity component	Vyndaqel analysis
Orange Book patent	U.S. Patent No. 8,309,605
Listed patent expiration	July 11, 2028, based on public patent records
Orphan-drug exclusivity	Historically applied to the original Vyndaqel indication; the seven-year period has expired
New chemical entity exclusivity	Not a current barrier
Biosimilar exclusivity	Not applicable because tafamidis is a small molecule
30-month stay	Potentially applicable after Pfizer's timely infringement action
Earliest generic entry	Controlled by patent disposition, settlement terms and FDA approval

Vyndaqel's orphan-drug designation provided regulatory exclusivity for the approved orphan indication, but that period does not remain a current barrier to an ANDA applicant. Orphan exclusivity also does not provide the same product-wide protection as a patent. It is tied to the designated disease or condition and statutory orphan-use requirements.[4]

What was the Paragraph IV challenge in Pfizer v. Aurobindo?

Aurobindo's ANDA certification challenged Pfizer's listed patent. The precise legal significance of the certification was that Aurobindo represented to FDA that the proposed generic product could be approved notwithstanding the listed patent because the patent was invalid, unenforceable or not infringed.

Pfizer responded by filing the Delaware action. The complaint sought the standard Hatch-Waxman remedies, including:

• A declaration that Aurobindo's proposed product would infringe the asserted patent.
• An injunction preventing commercial manufacture, use, offer for sale or sale before patent expiration.
• A declaration that the patent remained valid and enforceable.
• An order delaying approval or launch of Aurobindo's ANDA product until the statutory patent protections expired.

The case did not involve a claim that Aurobindo had already marketed a generic product. The dispute was based on the ANDA filing and the certification notice.

What was the litigation status and outcome?

The public docket identifies the action as an ANDA dispute rather than a reported patent trial involving a final infringement or invalidity opinion. The litigation record does not establish a publicly reported judgment holding U.S. Patent No. 8,309,605 invalid or unenforceable.

No public merits ruling should be treated as having eliminated Pfizer's patent rights. In pharmaceutical patent analysis, the absence of a reported invalidity decision is material. A dismissal, settlement or other procedural termination does not by itself establish that the patent was valid, infringed or enforceable.

Did Pfizer and Aurobindo reach a settlement?

The public record does not provide a reported judicial finding that the patent was invalid or unenforceable. Hatch-Waxman cases frequently conclude through confidential settlement agreements, stipulated dismissal or consent orders. Unless the settlement agreement or a related FTC filing discloses launch terms, the exact generic entry date, consideration and restrictions cannot be inferred from the docket alone.

The central commercial question is therefore whether Aurobindo received a license to launch before the listed 2028 patent expiration. A docket termination, without disclosed settlement terms, does not answer that question.

How strong was Pfizer's Vyndaqel patent estate?

Pfizer's estate was commercially meaningful but concentrated. The principal litigation record centered on one identified Orange Book patent rather than a large group of independently layered patents covering active ingredient, formulation, method of use and manufacturing.

Patent-estate factor	Assessment
Active-ingredient protection	Meaningful through U.S. Patent No. 8,309,605
Formulation protection	Tied closely to the asserted composition claims
Method-of-use protection	Important to the broader tafamidis franchise, but not the apparent core of this action
Manufacturing barriers	Potentially relevant, but not independently sufficient without an asserted patent
Regulatory exclusivity	Original orphan exclusivity has expired
Biosimilar protection	Not applicable
Litigation diversification	Limited if only one principal Orange Book patent is asserted
Generic design-around risk	Dependent on whether an ANDA applicant can use a different salt, formulation or noninfringing composition

The estate's strength derived from the importance of tafamidis itself and the difficulty of commercializing a therapeutically equivalent product without practicing the claimed drug substance or composition. Its weakness was concentration. If the asserted patent were invalidated or found not infringed, the remaining regulatory barriers would be comparatively limited.

What generic entry risks existed for Pfizer?

The key generic-entry scenarios were:

Launch after patent expiration

This is the lowest-litigation-risk scenario. Aurobindo could launch after the patent's expiration and after FDA approval, assuming no separate enforceable patent or regulatory restriction blocked the product.

Authorized or licensed early entry

A settlement could permit launch before July 2028. The economic impact would depend on the licensed date, the number of generic entrants and the scope of any launch restrictions.

At-risk launch

Aurobindo could launch before final resolution of the patent dispute, accepting potential damages and injunction exposure if Pfizer prevailed. At-risk launch would have exposed Aurobindo to substantial liability because Vyndaqel and Vyndamax address high-value specialty indications.

Noninfringing formulation

Aurobindo could pursue a formulation or salt that avoids the asserted claims. That strategy would require FDA approval of the alternative product and a convincing noninfringement position based on the ANDA's actual composition.

How did the case affect Pfizer's revenue exposure?

Tafamidis became one of Pfizer's highest-value specialty franchises. Pfizer reported Vyndaqel and Vyndamax as a combined product category in its financial reporting. The franchise generated approximately $3.3 billion in 2023 revenue and approximately $4.0 billion in 2024 revenue, making generic entry a material exposure for Pfizer's specialty and cardiovascular businesses.[5]

The commercial risk is greater than the revenue associated with Vyndaqel alone because a generic tafamidis product could affect prescribing, payer coverage and price expectations across the tafamidis franchise. The impact would depend on whether the generic product matched Vyndaqel's tafamidis meglumine presentation, targeted the Vyndamax indication, or entered through a separate regulatory pathway.

How does Pfizer v. Aurobindo compare with biosimilar litigation?

This was not a biosimilar case. Tafamidis is a chemically synthesized small-molecule drug, and Aurobindo proceeded through the ANDA pathway. The relevant framework was patent certification under the Hatch-Waxman Act, not the Biologics Price Competition and Innovation Act.

Issue	Pfizer v. Aurobindo	Biosimilar litigation
Product type	Small molecule	Biologic
FDA pathway	ANDA	351(k) application
Patent disclosure	Orange Book	Patent Dance and related disclosures
Challenge mechanism	Paragraph IV certification	BPCIA patent-resolution procedures
Substitution	Governed by generic-substitution rules	Depends on interchangeability designation and state law
Patent timing	30-month stay may apply	Different statutory framework

What geographic coverage did Pfizer have?

The action was filed in the District of Delaware, a leading venue for U.S. pharmaceutical patent litigation. The asserted U.S. patent provided protection only in the United States. Pfizer's international protection depended on separate national patent rights, regulatory exclusivities and local litigation outcomes.

An ANDA judgment or settlement in Delaware would not determine generic entry in Europe, Japan, Canada or other markets. The commercial effect of the case was therefore primarily U.S.-specific.

Key Takeaways

• Pfizer v. Aurobindo, 1:20-cv-01528, concerned Aurobindo's ANDA for generic tafamidis meglumine, the active ingredient in Vyndaqel.
• Pfizer's principal asserted patent was U.S. Patent No. 8,309,605.
• Public patent records identify July 11, 2028 as the patent's listed expiration date.
• The case was a Paragraph IV Hatch-Waxman action, not a biosimilar proceeding.
• The original orphan-drug exclusivity period is no longer a current barrier to generic entry.
• The public record does not establish a reported merits judgment invalidating Pfizer's patent.
• The estate was commercially valuable but concentrated around a central composition patent.
• Tafamidis generated roughly $4.0 billion in Pfizer revenue in 2024, making generic launch timing financially material.
• Exact settlement terms and any licensed early-entry date should not be inferred without a disclosed agreement or regulatory filing.

FAQs About Pfizer v. Aurobindo Pharma

What is Pfizer's tafamidis patent number?

The principal patent involved in the action was U.S. Patent No. 8,309,605, covering tafamidis meglumine and related pharmaceutical compositions.

Is tafamidis a biologic?

No. Tafamidis is a small-molecule drug. A generic tafamidis product is regulated through the ANDA pathway rather than the biosimilar pathway.

Can a generic launch before July 2028?

Potentially, but only if the applicant obtains a license, prevails in litigation, avoids the asserted claims, or otherwise establishes a lawful basis for earlier approval and commercialization.

Does the case eliminate Pfizer's Vyndaqel patent?

No public merits ruling identified in the litigation establishes that U.S. Patent No. 8,309,605 was invalidated or rendered unenforceable.

Why is the case important to Pfizer investors?

Tafamidis is a major Pfizer revenue franchise. Generic entry could reduce prices and volumes across the Vyndaqel and Vyndamax business, depending on the timing and number of approved competitors.

References

1. U.S. Food and Drug Administration. (2019). Vyndamax (tafamidis) prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. FDA.
3. United States Patent and Trademark Office. (2012). U.S. Patent No. 8,309,605: Tafamidis meglumine and related pharmaceutical compositions. USPTO.
4. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. FDA.
5. Pfizer Inc. (2025). 2024 annual report. Pfizer Inc.
6. U.S. District Court for the District of Delaware. (2020). Pfizer Inc. v. Aurobindo Pharma Limited, No. 1:20-cv-01528. PACER docket.